Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Neoadjuvant Pembrolizumab +/- Chemotherapy in Operable Stage IA3-IIA NSCLC
NCT04638582Phase 2Terminated
- Sponsor
- McGill University Health Centre
- Start
- Aug 2022
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by McGill University Health Centre. Primary endpoint: Circulating Tumor DNA Resolution up to 2 years. Started Aug 2022; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04638582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04638582.